p-ErbB2/HER2 Antibody (7F8): sc-81508

p-Neu Antibody (7F8) is a mouse monoclonal IgG1 antibody that detects Neu in mouse, rat, human, and canine samples through applications such as western blotting (WB) and immunoprecipitation (IP). p-Neu (7F8) antibody specifically recognizes phosphorylated forms of Neu, which is crucial for understanding Neu′s role in various signaling pathways associated with cancer progression. Neu, also known as HER2, is a member of the ErbB family of receptor tyrosine kinases and plays a significant role in cell growth and differentiation. Neu is primarily located at the cell membrane, where Neu interacts with other receptors and signaling molecules, facilitating the transduction of extracellular signals that promote cellular proliferation and survival. This localization allows Neu to participate in critical processes such as tissue development and repair, and Neu dysregulation is implicated in the etiology of several aggressive cancers, including breast and gastric cancers. The phosphorylation of Neu at specific tyrosine residues, such as Tyr 1248, is essential for Neu interaction with downstream signaling proteins like GRB2 and Shc, which further propagate the signaling cascade. Using anti-Neu antibody (7F8) in research can provide insights into the mechanisms of Neu-mediated signaling and oncogenesis implications, making anti-Neu antibody (7F8) an invaluable tool for cancer research and therapeutic development.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-ErbB2/HER2 Antibody (7F8) References:

1. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.  |  Moulder, SL., et al. 2001. Cancer Res. 61: 8887-95. PMID: 11751413
2. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta.  |  Wang, SE., et al. 2006. Cancer Res. 66: 9591-600. PMID: 17018616
3. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas.  |  Taniyama, K., et al. 2008. Breast Cancer. 15: 231-40. PMID: 18264744
4. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.  |  Fereshteh, MP., et al. 2008. Cancer Res. 68: 3697-706. PMID: 18483252
5. Novel luciferase-based reporter system to monitor activation of ErbB2/Her2/neu pathway noninvasively during radiotherapy.  |  Wolf, F., et al. 2011. Int J Radiat Oncol Biol Phys. 79: 233-8. PMID: 20934271
6. Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells.  |  Lee, JS., et al. 2013. Phytother Res. 27: 713-20. PMID: 22767439
7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.  |  Kurebayashi, J., et al. 2015. Breast Cancer. 22: 292-9. PMID: 23749689
8. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.  |  Baumann, J., et al. 2016. BMC Cancer. 16: 551. PMID: 27464732
9. Neu differentiation factors: a family of alternatively spliced neuronal and mesenchymal factors.  |  Ben-Baruch, N. and Yarden, Y. 1994. Proc Soc Exp Biol Med. 206: 221-7. PMID: 7912439
10. HER-2/neu signal transduction in human breast and ovarian cancer.  |  Reese, DM. and Slamon, DJ. 1997. Stem Cells. 15: 1-8. PMID: 9007217

The preferred antibody is Antibody (): sc-8.